Stock Performance

Showing 7096 articles
Business

DaVita's 37% Plunge: A Value Trap or a Golden Opportunity for Investors?

After a punishing year that saw its shares tumble over 37%, DaVita Inc. (DVA) is trading at a steep discount to its intrinsic value, according to fundamental analysis. With a P/E ratio significantly below industry peers, the dialysis giant presents a complex puzzle for long-term investors weighing regulatory headwinds against deep value.

Business

Silver ETF's Dramatic Plunge: A Buying Opportunity or a Trap?

The iShares Silver Trust (SLV) ETF plummeted nearly 30% in a single day, erasing months of gains. While technical indicators screamed overbought, the sell-off was triggered by shifting Fed policy expectations. Yet, long-term fundamentals for silver, driven by AI and green energy demand, remain compelling. We examine whether this is a dip to buy or a sign of deeper trouble.

Business

CytomX Therapeutics Surges on Promising Early Colorectal Cancer Data, Analysts Bullish on Probody Platform

Shares of CytomX Therapeutics (CTMX) jumped over 14% this week after early-stage clinical data for its lead Probody candidate, varsetatug maseatecan, in metastatic colorectal cancer drew positive reactions from Wall Street. The move highlights growing confidence in the company's conditionally activated antibody platform, designed to target tumors more precisely while sparing healthy tissue.